4.1 Article

Type 2 Diabetes Interacts With Alzheimer Disease Risk Factors to Predict Functional Decline

Journal

ALZHEIMER DISEASE & ASSOCIATED DISORDERS
Volume 34, Issue 1, Pages 10-17

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WAD.0000000000000332

Keywords

diabetes; Alzheimer disease; everyday functioning; subtle cognitive decline

Funding

  1. NIH [R01 AG049810, K24 AG026431]
  2. Alzheimer's Association [AARF-17-528918, AARG-17-500358, AARG-18-566254]
  3. U.S. Department of Veterans Affairs Clinical Sciences Research and Development Service [1IK2CX001415, 1IK2CX000938]
  4. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  5. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  6. National Institute on Aging
  7. National Institute of Biomedical Imaging and Bioengineering
  8. AbbVie
  9. Alzheimer's Association
  10. Araclon Biotech
  11. BioClinica Inc.
  12. Biogen
  13. Bristol-Myers Squibb Company
  14. CereSpir Inc.
  15. Cogstate
  16. Eisai Inc.
  17. Elan Pharmaceuticals Inc.
  18. Eli Lilly and Company
  19. EuroImmun
  20. F. Hoffmann-La Roche Ltd
  21. Genentech Inc.
  22. Fujirebio
  23. GE Healthcare
  24. IXICO Ltd
  25. Janssen Alzheimer Immunotherapy Research & Development, LLC
  26. Johnson & Johnson Pharmaceutical Research & Development LLC.
  27. Lumosity
  28. Lundbeck
  29. Merck Co. Inc.
  30. Meso Scale Diagnostics LLC
  31. NeuroRx Research
  32. Neurotrack Technologies
  33. Novartis Pharmaceuticals Corporation
  34. Pfizer Inc.
  35. Piramal Imaging
  36. Servier
  37. Takeda Pharmaceutical Company
  38. Transition Therapeutics
  39. Canadian Institutes of Health Research
  40. Alzheimer's Drug Discovery Foundation

Ask authors/readers for more resources

Objective: The current study examined the interactive effect of type 2 diabetes and Alzheimer disease (AD) risk factors on the rate of functional decline in cognitively normal participants from the Alzheimer's Disease Neuroimaging Initiative. Methods: Participants underwent annual assessments that included the Functional Activities Questionnaire, an informant-rated measure of everyday functioning. Multilevel modeling, controlling for demographic variables and ischemic risk, examined the interactive effects of diabetes status (diabetes, n=69; no diabetes, n=744) and AD risk factors in the prediction of 5-year longitudinal change in everyday functioning. One model was run for each AD risk factor, including: objectively-defined subtle cognitive decline (Obj-SCD), and genetic susceptibility [apolipoprotein E epsilon 4 (APOE epsilon 4) as well as cerebrospinal fluid beta-amyloid (A beta), total tau (tau), and hyperphosphorylated tau (p-tau). Results: The 3-way diabetesxAD risk factorxtime interaction predicted increased rates of functional decline in models that examined Obj-SCD, APOE epsilon 4, tau, and p-tau positivity, but not A beta positivity. Conclusions: Participants with both diabetes and at least 1 AD risk factor (ie, Obj-SCD, APOE epsilon 4, tau, and p-tau positivity) demonstrated faster functional decline compared with those without both risk factors (diabetes or AD). These findings have implications for early identification of, and perhaps earlier intervention for, diabetic individuals at risk for future functional difficulty.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available